Brokerages predict that Antares Pharma Inc (NASDAQ:ATRS) will report earnings per share (EPS) of ($0.02) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Antares Pharma’s earnings. The lowest EPS estimate is ($0.04) and the highest is ($0.01). Antares Pharma also posted earnings of ($0.02) per share during the same quarter last year. The company is expected to issue its next quarterly earnings results on Tuesday, March 12th.

On average, analysts expect that Antares Pharma will report full-year earnings of ($0.10) per share for the current year, with EPS estimates ranging from ($0.12) to ($0.07). For the next year, analysts anticipate that the business will report earnings of $0.07 per share, with EPS estimates ranging from ($0.02) to $0.22. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last released its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.01. Antares Pharma had a negative return on equity of 59.08% and a negative net margin of 27.84%. The firm had revenue of $17.87 million during the quarter, compared to the consensus estimate of $15.13 million.

ATRS has been the subject of a number of research reports. BidaskClub raised Antares Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, July 17th. HC Wainwright set a $5.00 target price on Antares Pharma and gave the stock a “buy” rating in a report on Monday, October 1st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $4.00 target price on shares of Antares Pharma in a report on Friday, August 17th. ValuEngine raised Antares Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, August 8th. Finally, Jefferies Financial Group lifted their price target on Antares Pharma to $7.00 and gave the company a “buy” rating in a research report on Tuesday, October 2nd. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $5.44.

Shares of Antares Pharma stock traded down $0.04 on Tuesday, reaching $3.32. 961,200 shares of the stock were exchanged, compared to its average volume of 1,265,586. The company has a quick ratio of 1.83, a current ratio of 2.29 and a debt-to-equity ratio of 1.03. Antares Pharma has a twelve month low of $1.68 and a twelve month high of $3.93. The company has a market capitalization of $573.45 million, a price-to-earnings ratio of -30.18 and a beta of 0.55.

In related news, Director Jacques Gonella sold 400,000 shares of Antares Pharma stock in a transaction that occurred on Tuesday, October 2nd. The stock was sold at an average price of $3.79, for a total transaction of $1,516,000.00. Following the completion of the transaction, the director now directly owns 9,585,848 shares in the company, valued at $36,330,363.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Robert F. Apple sold 43,000 shares of Antares Pharma stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $3.75, for a total value of $161,250.00. Following the transaction, the chief executive officer now owns 1,573,562 shares of the company’s stock, valued at $5,900,857.50. The disclosure for this sale can be found here. 12.20% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in ATRS. Mycio Wealth Partners LLC purchased a new position in Antares Pharma during the second quarter valued at approximately $6,278,000. FMR LLC raised its position in Antares Pharma by 38.8% during the second quarter. FMR LLC now owns 3,640,800 shares of the specialty pharmaceutical company’s stock valued at $9,393,000 after acquiring an additional 1,018,300 shares in the last quarter. BlackRock Inc. raised its position in Antares Pharma by 7.3% during the second quarter. BlackRock Inc. now owns 9,805,325 shares of the specialty pharmaceutical company’s stock valued at $25,298,000 after acquiring an additional 664,681 shares in the last quarter. JPMorgan Chase & Co. raised its position in Antares Pharma by 112.2% during the third quarter. JPMorgan Chase & Co. now owns 941,117 shares of the specialty pharmaceutical company’s stock valued at $3,162,000 after acquiring an additional 497,523 shares in the last quarter. Finally, United Services Automobile Association raised its position in Antares Pharma by 1,453.0% during the second quarter. United Services Automobile Association now owns 405,261 shares of the specialty pharmaceutical company’s stock valued at $21,147,000 after acquiring an additional 379,166 shares in the last quarter. Institutional investors own 37.39% of the company’s stock.

Antares Pharma Company Profile

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Featured Article: Liquidity

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.